Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis

scientific article

Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1013234976
P356DOI10.1186/AR4672
P932PMC publication ID4220089
P698PubMed publication ID25059342
P5875ResearchGate publication ID264246366

P50authorJérôme AvouacQ45580503
Jean-François ZaguryQ64750696
P2093author name stringYannick Allanore
Hadley Mouhsine
Hervé Do
Lucille Desallais
Rojo Ratsimandresy
Matthieu Montes
Maxime Fréchet
Muriel Elhai
P2860cites workCD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouseQ34792036
Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeletonQ36077865
Vaccination with cytokines in autoimmune diseasesQ37165366
Anti-cytokine therapeutics: history and updateQ37515918
Animal models of systemic sclerosis: prospects and limitationsQ37771308
Active immunization against murine TNFalpha peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection.Q40490993
Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvementQ40491920
Relationship between interleukin-6 and cardiac involvement in systemic sclerosisQ43812359
Interleukin-1, Interleukin-2, Interleukin-4, Interleukin-6, Tumor Necrosis Factor α, and Interferon-γ Levels in Sera from Patients With SclerodermaQ44338106
Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin.Q46597820
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosisQ47763592
Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.Q53803121
SclerodermaQ54165664
Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.Q54335579
Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis.Q54599837
Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosisQ57265274
In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late diseaseQ71607968
Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6 Pa/Pa miceQ72356859
A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin miceQ72680204
Development of the tight-skin phenotype in immune-deficient miceQ73661511
Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosisQ74452502
Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking sclerodermaQ77319152
Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritisQ77742326
Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosisQ78169196
Connective tissue development in subcutaneously implanted polyvinyl sponge. I. Biochemical changes during developmentQ79111307
Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modellingQ80350639
Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 productionQ81714149
Active immunization against IL-23p19 improves experimental arthritisQ82081093
Blockade of interleukin-6 receptor alleviates disease in mouse model of sclerodermaQ82401401
[Interactions between fibrillin-1 and tgf-beta: consequences and human pathology]Q83393406
Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosisQ83499702
IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host diseaseQ84586437
P4510describes a project that usesImageJQ1659584
P433issue4
P921main subjectimmunizationQ1415366
active immunizationQ3425478
P304page(s)R157
P577publication date2014-07-24
P1433published inArthritis Research and TherapyQ15757229
P1476titleTargeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis
P478volume16

Reverse relations

cites work (P2860)
Q40047502A modified graft-versus-host-induced model for systemic sclerosis, with pulmonary fibrosis in Rag2-deficient mice
Q45920167An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
Q39450087An update on biomarker discovery and use in systemic sclerosis.
Q26741264Current perspectives on the immunopathogenesis of systemic sclerosis
Q61445191Deciphering the Potential Pharmaceutical Mechanism of GUI-ZHI-FU-LING-WAN on Systemic Sclerosis based on Systems Biology Approaches
Q100559306Dermal fibroblasts have different extracellular matrix profiles induced by TGF-β, PDGF and IL-6 in a model for skin fibrosis
Q90363927Drugs in phase I and phase II clinical trials for systemic sclerosis
Q91845024Emerging targets of disease-modifying therapy for systemic sclerosis
Q37611647Epigenetic Regulation of Interleukin 6 by Histone Acetylation in Macrophages and Its Role in Paraquat-Induced Pulmonary Fibrosis
Q49989946Fli1-haploinsufficient dermal fibroblasts promote skin-localized transdifferentiation of Th2-like regulatory T cells
Q37614491IL-1 Vaccination Is Suitable for Treating Inflammatory Diseases
Q36499879Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys
Q58785737Interleukin-6 and Type-I Collagen Production by Systemic Sclerosis Fibroblasts Are Differentially Regulated by Interleukin-17A in the Presence of Transforming Growth Factor-Beta 1
Q98577683Interleukin-6 promotes proliferative vitreoretinopathy by inducing epithelial-mesenchymal transition via the JAK1/STAT3 signaling pathway
Q37471585Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
Q28072568Pathophysiology of systemic sclerosis
Q94219607Potential Vaccines for Treating Crohn's Disease
Q40683161Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
Q51250934Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor β and Activate Fibroblasts.
Q28073706Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis
Q36682162Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways
Q38636049Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy
Q28072943Targeted Therapy in Systemic Sclerosis
Q89717413The mighty fibroblast and its utility in scleroderma research
Q64940918Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
Q53165286Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.

Search more.